<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57420">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358564</url>
  </required_header>
  <id_info>
    <org_study_id>14-000837</org_study_id>
    <nct_id>NCT02358564</nct_id>
  </id_info>
  <brief_title>Gut Permeability, Sensitivity and Symptomatology</brief_title>
  <acronym>GPSS</acronym>
  <official_title>Gut Permeability, Sensitivity and Symptomatology: Is There a Link and Explanation for Exacerbation of Symptoms Post Meals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Erlangen-NÃ¼rnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To better understand the relationship between gut barrier function and the symptomatology
      and pathophysiology of IBS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent of complete epithelial cell loss</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Visceral Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrointestinal Permeability Test</intervention_name>
    <description>This test will involve ingesting a solution followed by urinalysis</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Upper Endoscopy</intervention_name>
    <description>You will have an upper endoscopy</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal Barostat and Infusion of Fats</intervention_name>
    <description>Feeding tube will be placed as well as a small balloon in the rectum</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Irritable Bowel Syndrome Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age 18 to 70 years

          -  No restrictions on Hospital Anxiety and Depression score

          -  No abdominal surgery (except appendectomy).

          -  Written informed consent

        Exclusion criteria

          -  Females who are pregnant, breastfeeding or hysterectomized.

          -  Use of tobacco products within the past 6 months (since nicotine may affect
             intestinal permeability)

          -  Use of NSAIDs or aspirin within the past week (since NSAIDs affect intestinal
             permeability)

          -  Use of oral corticosteroids within the previous 6 weeks

          -  Ingestion of artificial sweeteners such as Splenda TM (sucralose), Nutrasweet TM
             (aspartame), lactulose or mannitol 2 days before the study tests begins, e.g. foods
             to be avoided are sugarless gyms or mints and diet soda.

          -  Ingestion of any prescription, over the counter, or herbal medications which can
             affect gastrointestinal transit 7 days before the study begins.

          -  Proton pump inhibitors.

          -  Antibiotics for the preceding 60 days before the start of the study.

          -  (vii) Alcohol intake beyond the recommended safe limit (&lt;21 unites per week)

          -  Bleeding disorders or medications that increase risk of bleeding from mucosal
             biopsies.

          -  Known allergy to fluorescein

          -  Inflammatory bowel diseases, celiac disease.

          -  Clinically significant bradycardia with potential to interfere with procedure induced
             vagal tone (Investigators may be guided by a cut-off heart rate of &lt; 50
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lesley Houghton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daryl Jones, Ph.D.</last_name>
    <phone>9049538101</phone>
    <email>Jones.Daryl@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daryl Jones</last_name>
      <phone>904-953-8101</phone>
      <email>Jones.Daryl@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 12, 2016</lastchanged_date>
  <firstreceived_date>January 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Lesley A. Houghton</investigator_full_name>
    <investigator_title>PhD, FSB, RFF, FACG, AGAF, Professor of Medicine, Division of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>IBS</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Visceral Hypersensitivity</keyword>
  <keyword>Permeability</keyword>
  <keyword>Small Bowel</keyword>
  <keyword>Lactulose</keyword>
  <keyword>Mannitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
